Nesvacumab: Difference between revisions
Content deleted Content added
Ozzie10aaaa (talk | contribs) No edit summary |
m Dating maintenance tags: {{Cn}} |
||
| Line 37: | Line 37: | ||
'''Nesvacumab''' is an experimental [[monoclonal antibody]] originally designed for the treatment of cancer. It targets the protein [[angiopoietin 2]].<ref>[http://www.ama-assn.org/resources/doc/usan/nesvacumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab], ''[[American Medical Association]]''.</ref><ref name="Hussain_2019">{{cite journal | vauthors = Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA | title = Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease | journal = Expert Opinion on Investigational Drugs | volume = 28 | issue = 10 | pages = 861–869 | date = October 2019 | pmid = 31513439 | doi = 10.1080/13543784.2019.1667333 }}</ref> {{as of|2017|5}}, it is in [[Phase II clinical trial]]s for the treatment of [[diabetic macular edema]].<ref>{{clinicalTrialsGov|NCT02713204|Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)}}</ref><ref>{{clinicalTrialsGov|NCT02712008|Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)}}</ref> |
'''Nesvacumab''' is an experimental [[monoclonal antibody]] originally designed for the treatment of cancer. It targets the protein [[angiopoietin 2]].<ref>[http://www.ama-assn.org/resources/doc/usan/nesvacumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab], ''[[American Medical Association]]''.</ref><ref name="Hussain_2019">{{cite journal | vauthors = Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA | title = Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease | journal = Expert Opinion on Investigational Drugs | volume = 28 | issue = 10 | pages = 861–869 | date = October 2019 | pmid = 31513439 | doi = 10.1080/13543784.2019.1667333 }}</ref> {{as of|2017|5}}, it is in [[Phase II clinical trial]]s for the treatment of [[diabetic macular edema]].<ref>{{clinicalTrialsGov|NCT02713204|Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)}}</ref><ref>{{clinicalTrialsGov|NCT02712008|Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)}}</ref> |
||
This drug is being developed by [[Regeneron Pharmaceuticals]].{{cn}} |
This drug is being developed by [[Regeneron Pharmaceuticals]].{{cn|date=February 2023}} |
||
== References == |
== References == |
||
Revision as of 21:29, 8 February 2023
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Angiopoietin 2 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6440H9966N1722O2008S38 |
| Molar mass | 144860.89 g·mol−1 |
Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2.[1][2] As of May 2017[update], it is in Phase II clinical trials for the treatment of diabetic macular edema.[3][4]
This drug is being developed by Regeneron Pharmaceuticals.[citation needed]
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association.
- ^ Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA (October 2019). "Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease". Expert Opinion on Investigational Drugs. 28 (10): 861–869. doi:10.1080/13543784.2019.1667333. PMID 31513439.
- ^ Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
- ^ Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |